Carisma Therapeutics reports initial patient dosed in Phase 1 study of CT-0525, an innovative HER2-focused CAR-monocyte therapy.

May 21st latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The FDA has greenlit Imdelltra™ (tarlatamab-dlle), marking the first T-cell engager therapy for extensive-stage small cell lung cancer.

Proteologix’s lineup includes PX128, a bispecific antibody that targets both IL-13 plus TSLP. PX128 is poised to advance into phase 1 development for the treatment of moderate to severe atopic dermatitis and asthma.

Bayer Begins Phase I Trial of 225Ac-PSMA-Trillium Targeted Radionuclide Therapy for Advanced Metastatic Prostate Cancer.

The U.S. FDA has approved Bristol Myers Squibb's CAR T cell therapy Breyanzi for treating relapsed or refractory follicular lymphoma.

Genentech Announces Favorable Phase Ib Outcomes for Dual GLP-1/GIP Receptor Agonist CT-388 in Obesity Patients.

The trial involves the use of IMUNON’s IMNN-001, a DNA-based immunotherapy, alongside bevacizumab, in patients with this condition.

Monopar Therapeutics is advancing its Phase 1 dosimetry clinical trial for MNPR-101-Zr, a potential treatment for advanced cancers.

ATHEx Biotech has received approval from the FDA to commence clinical trials for ATX-01, a pioneering microRNA-based treatment for Myotonic Dystrophy Type 1 (DM1).

ImmPACT Bio has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the Phase 1b/2 study of IMPT-514, a novel CAR T-cell therapy.

Skyhawk Therapeutics has made significant progress with its innovative drug candidate, SKY-0515, which is engineered to be an RNA splicing modifier.